We serve Chemical Name:(4-bromo-6-chloropyridin-3-yl)boronic acid CAS:957062-85-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-bromo-6-chloropyridin-3-yl)boronic acid
CAS.NO:957062-85-0
Synonyms:4-Bromo-6-chloropyridine-3-boronic acid;4-Bromo-2-chloropyridine-5-boronic acid;4-bromo-6-chloropyridin-3-ylboronic acid
Molecular Formula:C5H4BBrClNO2
Molecular Weight:236.25900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:390ºC at 760 mmHg
Density:1.9g/cm3
Index of Refraction:1.619
PSA:53.35000
Exact Mass:234.92100
LogP:0.17730
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Bromo-6-chloropyridine-3-boronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-6-chloropyridin-3-ylboronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-6-chloropyridin-3-ylboronic acid Use and application,4-Bromo-2-chloropyridine-5-boronic acid technical grade,usp/ep/jp grade.
Related News: As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base. Benzoic acid (R)-2-ethoxycarbonylmethyl-2-methyl-but-3-enyl ester manufacturers The superiority to psilocybin is due in part to the incorporation of a conjugated amplification moiety (CAM) that enhances 5-HT2A specific effects while reducing non-specific effects. Nucleotidyltransferase, deoxyribonucleate, g (humanmitochondria-encoded mitochondria-associated gene POLG fragment) suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 1-N’,2-N’-dicyclopentylethanedihydrazide vendor & factory.
